CIBC Private Wealth Group’s Neurocrine Biosciences NBIX Stock Holding History

CIBC Private Wealth Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.1M	Sell	7,726 -255	-3%	-$36.9K	﹤0.01%	684
2025 Q3	$1.12M	Buy	7,981 +7,935	+17,250%	+$1.08M	﹤0.01%	675
2025 Q2	$5.78K	Sell	46 -13	-22%	-$1.49K	﹤0.01%	2424
2025 Q1	$5.17K	Sell	59 -986	-94%	-$125K	﹤0.01%	2444
2024 Q4	$145K	Sell	1,045 -107	-9%	-$13.2K	﹤0.01%	1285
2024 Q3	$133K	Sell	1,152 -3	-0.3%	-$411	﹤0.01%	1369
2024 Q2	$164K	Sell	1,155 -6,472	-85%	-$888K	﹤0.01%	1198
2024 Q1	$1.08M	Buy	+7,627	New	+$1.04M	﹤0.01%	658
2023 Q1	–	Sell	-24,925	Closed	-$2.98K	–	919
2022 Q4	$2.98K	Buy	24,925 +3,846	+18%	+$450K	﹤0.01%	748
2022 Q3	$2.24M	Buy	+21,079	New	+$2.14M	0.01%	464

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CIBC Private Wealth Group's NBIX Position: Q4 2025 in Review

CIBC Private Wealth Group reduced its Neurocrine Biosciences (NBIX) stake by 3.2% in Q4 2025, selling an estimated $36.9K and leaving 7,726 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #684.

CIBC Private Wealth Group first reported a position in NBIX in Q3 2022 and has held it in 10 quarters since. The position peaked at $2.24M in Q3 2022. 731 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

CIBC Private Wealth Group held 7,726 shares of Neurocrine Biosciences worth $1.1M as of Q4 2025.
CIBC Private Wealth Group sold 255 Neurocrine Biosciences shares in Q4 2025, an estimated $36.9K.
Neurocrine Biosciences made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #684 holding.
CIBC Private Wealth Group first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 10 quarters since.
CIBC Private Wealth Group's Neurocrine Biosciences position peaked at $2.24M in Q3 2022.
731 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.